National Psoriasis Foundation clinical consensus on disease severity
National Psoriasis Foundation clinical consensus on disease severity
复制标题
DOI：
10.1001/archderm.143.2.239
复制
发表时间：
2007-02-01
影响因子：
--
通讯作者：
Horn, Elizabeth J.
中科院分区：
文献类型：
--
作者：
Pariser, David M.;Bagel, Jerry;Horn, Elizabeth J.
目的：国家牛皮癣基金会医学委员会召集了一个工作组来评估当前轻度、中度和重度牛皮癣的严重程度标准，并根据当前的临床实践和与治疗意图相关的两级严重程度分类提出建议。参与者：该志愿者工作组由David M. Pariser医学博士领导，包括Jerry Bagel医学博士，Joel M. Gelfand医学博士，MSCE, Neil J. Korman医学博士，Christopher T. Ritchlin医学博士，Bruce E. Strober医学博士，Abby S. Van Voorhees医学博士和Melodic Young， MSN， RN, AN P.会议通过电话会议举行，由国家牛皮癣基金会协调和资助。证据：该工作组审查了牛皮癣严重程度标准和其他已发表的牛皮癣共识声明。目前的护理标准和专家意见被用于告知这一过程。共识过程：在工作组会议的基础上，在David M. Pariser医学博士的指导下，Elizabeth J. Horn博士起草了一份声明，提交给工作组，并由工作组审查和批准。该声明随后由Robert E. Kalb医学博士、Gerald G. Krueger医学博士和Alan Menter医学博士审查并通过。2006年3月2日，在医学委员会会议上，国家牛皮癣基金会医学委员会以多数票审查并通过了该声明。结论：该临床共识声明提出了斑块型银屑病治疗的两层体系，比目前的体系更准确地反映了患者在临床实践中的治疗方式。本声明的重点是斑块型银屑病，旨在帮助医疗专业人员和保险支付者了解这两类银屑病患者，并为这些患者选择合适的治疗方法。
Objectives: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate the current severity criteria of mild, moderate, and severe psoriasis and to make recommendations concerning a 2-tiered categorization of severity based on Current clinical practice and related to intent to treat.Participants: This volunteer task force, led by David M. Pariser, MD, included Jerry Bagel, MD, Joel M. Gelfand, MD, MSCE, Neil J. Korman, MD, PhD, Christopher T. Ritchlin, MD, Bruce E. Strober, MD, PhD, Abby S. Van Voorhees, MD, and Melodic Young, MSN, RN, AN P. Meetings were held by teleconference and were coordinated and funded by the National Psoriasis Foundation.Evidence: This task force reviewed psoriasis severity criteria and other published psoriasis consensus statements. Current standards of care and expert opinion were used to inform the process.Consensus Process: Based on meetings of the task force and under the guidance of David M. Pariser, MD, a statement was drafted by Elizabeth J. Horn, PhD, presented to the task force, and reviewed and approved by the task force. This statement was then reviewed and approved by Robert E. Kalb, MD, Gerald G. Krueger, MD, and Alan Menter, MD. The National Psoriasis Foundation Medical Board reviewed and endorsed this statement by a majority vote on March 2, 2006, at the medical board meeting.Conclusions: This clinical consensus statement proposes a 2-tiered system for plaque psoriasis therapy that reflects more accurately than the current system how patients are treated in clinical practice. This statement, focused on plaque psoriasis, is intended to assist medical professionals and insurance payers in understanding these 2 categories of patients with psoriasis and choosing appropriate therapies for these patients.